Fabry’s disease is an inherited lysosomal storage disease in which the enzyme á-galactosidase (á-GAL), which breaks down the compound globotriaosylceramide, does not function properly or is ...

ANGIOKERATOMA corporis diffusum universale, or Fabry's disease, was regarded as a dcrmatologie curiosity until a description by Ruiter and Pompen1 from the Netherlands in 1939 suggested that it was ...

Learn about the Ten-year outcome of enzyme replacement therapy with Agalsidase beta in patients with Fabry disease.

The company recently reported impressive data for its gene therapy in Fabry's disease. The company's Fabry's disease gene therapy program has a lead over competition like Sangamo and Amicus ...

Large Scale Biology, a Vacaville company working to produce biotechnology drugs in tobacco plants, said the Food and Drug Administration designated its experimental treatment for Fabry's disease ...

Derek Lawson may finally get some relief from what doctors diagnosed as Fabry's disease, a rare, deadly, genetic disorder that keeps his body from breaking down a naturally occurring fatty protein.

Fabry's disease (also known as Anderson–Fabry's disease) was originally described in 1898. 3, 4 The condition is characterized by a deficiency in the enzyme α-galactosidase A, which leads to ...

After stepping in to relieve a drug shortage that forced Fabry’s disease patients to ration their drug supplies, Shire has pulled its drug, Replagal, from FDA review. The company was set to go before ...

Two new studies offer hope to people suffering from the genetic fat storage disorder known as Fabry's disease, which arises from deficiency of an enzyme involved in the biodegradation of lipids ...

The "Fabry's Disease Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments" report has been added to ResearchAndMarkets ...

The report provides Fabry's Disease treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region ...

Fabry's disease, an X-linked lysosomal-storage disorder, is due to a deficiency of α-galactosidase A. 1 In the glycosphingolipid catabolic pathway, this enzyme removes the third sugar residue, a ...